InvestorsHub Logo
Followers 4
Posts 121
Boards Moderated 0
Alias Born 08/10/2005

Re: None

Saturday, 08/08/2015 11:55:53 AM

Saturday, August 08, 2015 11:55:53 AM

Post# of 15812
BREAKING NEWS ‘Rolapitant Approval on Track, says Mizuho’

TESARO Q2 shows Rolapitant approval on track, says Mizuho

Mizuho analyst Peter Lawson reiterates a Buy rating on TESARO with a $67 price target following the company’s Q2 results. A September 5 FDA action date for the oral version of rolapitant is upcoming, Lawson tells investors. He expects FDA approval with commercialization in Q4 for the NK-1 receptor antagonist.

Note# In October 2009, OPKO acquired Rolapitant
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OPK News